Clinical trialPhase 1Recruiting

NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor

A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors

NCT06134960 ↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome: Ongoing
Phase: Phase 1
Status: Recruiting
Study type: Interventional
Start: 16 November 2024
Expected end: 15 November 2027
Enrollment: 12 participants
Sites: 1
Primary outcomes: Incidence of Treatment Related adverse events (AEs); Dose-limiting toxicity (DLT) rate
Sponsor: Other
Results posted: No
Last update: 14 September 2026

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.